Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 30, 2013

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Aprepitant

Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT01334086 - Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy | Biotech Hunter | Biotech Hunter